ClinicalTrials.gg
Sign In
Not yet recruitingNCT06836102Updated Feb 20, 2025

Usage of Orange Peel Extract in Management of Epistaxis

An interventional study of Orange in Epistaxis, sponsored by Minia University. Not yet recruiting. Open to participants aged 5 Years to 15 Years. Per ClinicalTrials.gov, last updated 2025-02-20.

Sponsored by Minia University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 7 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
5 Years to 15 Years
Sex
All
01

Study summary

Efficacy of orange peel extract in treatment of epistaxis in children

Read the detailed description

Formulation of orange peel extract into gel substance and usage of it in local treatment of epistaxis

02

Conditions studied

  • Epistaxis

Browse trials for

03

In context

Epistaxis

96 studies on the registry are indexed under Epistaxis; 22 are open to participants now.

This study's planned enrollment of 60 is close to the median of 64 across 81 interventional studies indexed under Epistaxis.

Browse Epistaxis studies →

Lead sponsor

Minia University is the lead sponsor of 370 studies on the registry; 117 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Browse Minia University studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
5 Years to 15 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • children with anterior epistaxis from little's area

Exclusion criteria

Exclusion Criteria:

  • patient with nasal polyp.
  • patients with hematological abnormalities.
  • patients with general diseases affecting coagulation system.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    gel of Orange peel extract

    usage of gel of Orange peel extract as a local treatment of epistaxis

    Dietary Supplement: Orange

  • Active comparator
    nano-based gel of Orange peel extract

    usage of nano-based gel of Orange peel extract as a local treatment of epistaxis

    Dietary Supplement: Orange

  • Placebo comparator
    placebo

    usage of placebo in control cases

    Dietary Supplement: Orange

Interventions

  • Dietary supplementOrange

    usage of orange peel extract in gel layer in treatment of epistaxis

06

What researchers measure

Primary outcomes

  1. The potential of nano-based gel of Orange peel extract in management of epistaxis

    assessment of epistaxis ( amount, severity and frequency ) according to ESS ( Epistaxis Severity Score ) between patients in study groups

    Time frame: From enrollment to the end of treatment at 4 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Andrade MA, Barbosa CH, Shah MA, Ahmad N, Vilarinho F, Khwaldia K, Silva AS, Ramos F. Citrus By-Products: Valuable Source of Bioactive Compounds for Food Applications. Antioxidants (Basel). 2022 Dec 25;12(1):38. doi: 10.3390/antiox12010038. PubMed 36670900 ↗

Individual participant data

Plan to share: Yes — result

Supporting information: Informed consent form, Clinical study report

Time frame: 3 months

Access criteria: contact by emailing

Data sharing details ↗ · gmail.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2025; primary completion for Apr 2025, 2 months later.

Of 24 interventional studies with no phase under Epistaxis, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 25. This study's planned 2 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2025
First posted
Feb 20, 2025
StartEst.
Feb 2025
Primary completionEst.
Apr 2025
CompletionEst.
May 2025
Last update
Feb 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06836102
Lead sponsor
Minia University
Responsible party
Mostafa Nasr Zayed (lecturer of otorhinolaryngology Minia university, Minia University) — Principal investigator
First posted
Feb 20, 2025
Start date
Feb 2025 (estimated)
Primary completion
Apr 2025 (estimated)
Completion
May 2025 (estimated)
Last update
Feb 20, 2025

Study contacts

Mostafa Nasr Ahmed, consultant
Contact
drmostafanasr1988@gmail.com
+201007905656
Hanaa Bahaa El-khouly, consultant of pharmacognosy
Contact
hanaa.bahaaelkhouly@yahoo.com
+201001616758

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Orange

Other studies in this condition

Epistaxis →

Other studies from this sponsor

Minia University →

Start the discussion